|
| Status |
Public on Mar 24, 2017 |
| Title |
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
We studied the in vitro and in vivo efficacy of the HDAC inhibitor Givinostat/ITF2357 in BCP-ALL with CRLF2 rearrangements. We used BCP-ALL CRLF2- rearranged MHH-CALL4 and MUTZ5 cell lines as well as blasts from CRLF2 rearranged BCP-ALL patients and patients’ derived xenograft samples. We conclude that Givinostat may represent a novel and effective tool, in combination with current chemotherapy, to treat this subsets of ALL with poor prognosis and chemotherapy-related toxicity.
|
| |
|
| Overall design |
Gene expression was measured using Affymetrix platform in 5 pair of BCP-ALL patient derived xenograft samples treated or untreated ex vivo with Givinostat at 0.2 uM for 6 hours.
|
| |
|
| Contributor(s) |
Trentin L, Savino A |
| Citation(s) |
28331226, 39071567 |
| |
| Submission date |
Jan 27, 2016 |
| Last update date |
Aug 15, 2024 |
| Contact name |
Luca Trentin |
| E-mail(s) |
luca.trentin78@gmail.com
|
| Phone |
0039 049 8211466
|
| Organization name |
University of Padova
|
| Department |
Department of Women's and Children's Health
|
| Street address |
Via Giustiniani, 3
|
| City |
Padova |
| ZIP/Postal code |
35127 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
| Samples (10)
|
|
| Relations |
| BioProject |
PRJNA309937 |
Less...
More...